Over 30 years of investing in individual stocks. Extensive business experience with small to mid-size companies, including as CEO. Many hundreds of blog posts on financial and economic matters since 2008. Focus on value with catalysts for upside price action. Background as a physician and pharmaceutical inventor and entrepreneur, however focus now is global and involves almost all economic categories.
Hilary Kramer is the editor in chief of the subscription newsletters: Game Changers, Breakout Stocks Under $10, High Octane Trader, Absolute Capital Return Portfolio and Inner Circle. For more than a decade, Hilary was the CIO of a $5 billion global private equity fund. She has an MBA from the Wharton School at the University of Pennsylvania and a BS with honors from Wellesley College. She began her Wall Street career as an analyst at Morgan Stanley. Hilary is the author of The Little Book of Big Profits from Small Stocks (Wiley) and Ahead of the Curve: Nine Simple Ways to Create Wealth by Spotting Stock Trends (Free Press). To learn more about Hilary Kramer visit: http://GameChangerStocks.com.
Surgeon with a highly varied background. Mixture of buy and hold equities and higher risk securities and LEAP calls.
The picture is James K. Polk; one of our most successful and underrated presidents. Ran for office stating he would accomplish 4 things. Accomplished all four, died shortly after his term completely exhausted.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Doug K. Le Du is a preferred stock researcher, author of the book titled Preferred Stock Investing, syndicated writer and publisher of three monthly preferred stock newsletters.
Doug has been studying the preferred stock marketplace since 2002. In 2006 he published the first edition of Preferred Stock Investing which has been updated and re-published regularly since then.
Preferred Stock Investing teaches risk-averse investors how to screen, buy and sell the highest quality preferred stocks. The book lists all qualifying preferred stocks that have been issued since January 2001.
The ten selection criteria from Preferred Stock Investing filtered out the 57 preferred stocks from the big banks that would be claimed by the Global Credit Crisis and let pass the 13 issues from the big banks that were saved by acquisition. In 70 out of 70 cases, a 100% success rate for almost two years running, the preferred stock selection criteria found in Preferred Stock Investing protected preferred stock investors.
As a researcher, Doug researches the market price behavior of the highest quality preferred stocks and writes to you about trends and opportunities. His premium subscription service (described at www.PreferredStockInvesting.com) providers subscribers with email alerts of new preferred stock issues, access to his preferred stock catalogs and HotLists, a monthly newsletter just for premium subscribers and much more.
Doug's academic background is in economics and statistics. Doug retired from his position as Managing Director at one of the world's largest management consulting firms in 2002 to focus on preferred stock research. Doug does not sell preferred stocks nor is he a stock broker or financial adviser.
The author is a former hedge fund trader now working as an Independent Trader, Consultant and author of the Panick Value Research Report. The Panick Report is a newsletter and alert service focused on undervalued high yield preferred stock issues and some undervalued micro cap equities. Sign up in the Dividends section of the Seeking Alpha Marketplace to receive exclusive subscriber articles, daily sector updates, advance drafts of public articles and more. Email firstname.lastname@example.org for more information. See also my Panick Value Research Report Facebook site for tips on upcoming articles.
Williams Equity Research analyzes trading strategy, individual stocks, asset classes, market sectors, and risk to reward parameters in order to provide valuable insight to the Seeking Alpha community.
The author has over 10 years of experience in the financial markets working in areas of equities trading, complex product analysis, and risk management, as well as a graduate level education in the areas of petroleum engineering (full), law (partial), and finance (MBA, partial).
I started my education at the University of Chicago, my home town, and ended with 3 degrees from MIT. After graduation, I joined IBM and spent 11 exiting years with them in a variety of sales, marketing an product development posts. I was among the top six System Engineers, and my last assignment was managing the design of the first virtual memory (VM), multi-programming, multi-processor operating system.
After leaving IBM, I ran the east coast operations of a premier consulting firm working for both Wall Street and corporate customers. Our clients were most of the major technology and venture capital companies. I wrote the first Wall Street report on software and services.
Subsequently, I became Chairman and CEO of a smaller consumer products company and quickly turned the company profitable by doubling the sales in 2 years.
Next, I moved back to technology by heading the corporate development of a major communications firm, Western Union, that was just entering the exciting market growth opportunities in the cell phone, satellite communications and independent wire line phone industry.
I then returned to Wall Street full time, first for Shearson and then Merrill before working with smaller firms in both research and corporate finance and became well known by most technology investors.
Now, I formed a partnership and run a small fund and do corporate finance type work.
Zach is a biotech investor with PhD training in Biochemistry and Molecular Biology. In real life, he is a scientific writer specializing in continuing medical education. He hopes to provide a crucial piece of total due diligence as well as interesting insight into clinical findings that may impact readers' portfolios and lives.
Highly educated private investor with 35 years experience investing in individual stocks and an occasional ETF. I particularly like disruptive technology and growth stocks that are undervalued or beaten down.
MD, MBA. Professional experience in clinical research and at a top-tier management consulting firm, advising clients in the pharmaceutical and healthcare PE industry. Successfully invested in biotech for over a decade with a value-based approach
Having always been a learning machine, I speak five languages, have worked as a sales agent, project manager, translator, computer consultant, software engineer, built a house with my own hands, published books and essays on literature, philosophy and art, have written for magazines of various kinds in different countries.
After retiring early in 2004, little by little, I have become a fund manager for some friends and myself, following the principles of value investing laid out by Benjamin Graham, Phil Fisher, Charlie Munger and Warren Buffett. You can read about my thoughts on a suitable portfolio structure for early retirees here.
My articles should not be considered to be any kind of investment advice. What suits me well is not necessarily good for others, as successful investing is somewhat like a marriage: If only one is perfect, the marriage won’t work. So please do your own research and remember Benjamin Graham's advice: “The investor’s chief problem — and even his worst enemy — is likely to be himself.”
I run a very concentrated portfolio with 10-15 positions and invest for the long term. As of 12/2016, my largest position is Theravance Biopharma (TBPH), a company I had intensively and extensively researched long before any sell-side analyst noticed the stock. You can find my early work on TBPH on this site and my comprehensive in-depth research reports on all important pipeline assets here. I correctly predicted the evolution of the new GOLD guidelines for COPD, the sales trajectory of Vibativ and GSK's new Ellipta product range. My reports have been far ahead (in terms of depth, scope and reliability) of all sell-side work on TBPH. That said, I obviously make mistakes as well, although I've yet to make one that costs me serious money.
Other long-time favorites of mine are DaVita (DVA), IBM and a few European small caps which I have also partly covered on Seeking Alpha, e.g. Admiral (AMIGF), Fuchs Petrolub (FUPEF).
Biotech stock trading and investing for 25 years. PhD in biology, MS in computer science.
Extensive experiences in biotech/pharmaceutical companies, in both USA and China, serving middle to senior executive positions. After 12 years of research at top institutions/universities and 10 years of management in biotech/pharmaceutical industry, I am now a full time biotech investor/trader, residing at Las Vegas.
I mainly rely on fundamental analysis to pick biotech stocks, either long or short. I also use proprietary programs to aid my screening process. Currently, I am working with a group of advanced option traders in a quest to tame volatile biotech stocks.
I am an individual investor who has been actively involved in the healthcare and biotechnology space for over 15 years. I hold a PhD in the biomedical sciences and have worked in both large pharmaceutical and small biotech companies. I make investments based on the fundamentals of a company and if I believe they have a superior technology or products compared to the competition. I'm an investor who believes patience pays off.
Brian Marckx, CFA is the Senior Medical Device / Diagnostics Analyst with Zacks Investment Research. I cover small and micro-cap medical device and diagnostic companies. Focus is development-stage companies with novel and emerging technologies as well as already established names still flying under the radar.
Prior to joining Zacks, Brian worked as a high-yield bond analyst on Wachovia Securities’ institutional trading desks where he specialized in the healthcare and industrials industries. Prior to that he was an analyst in corporate finance at First Union National Bank. Brian has covered the medical device, pharmaceutical and biotechnology industries since joining Zacks.
Brian has been quoted in numerous publications including The Wall Street Journal, Barron's, Bloomberg-Businessweek and Kiplinger. His work has also been cited in various market studies and working papers including those from Massachusetts Institute of Technology, Deloitte & Touche, and Pharmaceutical Manufacturing. Brian graduated with a B.S. in Finance from St. John Fisher College and received his MBA from Wake Forest University. Brian is also a Chartered Financial Analyst charterholder.
Sharon di Stefano has spent 20 years as an analyst, beginning her career at Smith Barney, Harris Upham & Co. specializing in medical devices, pharmaceuticals, healthcare information technology, and biopharmacology. Ms. di Stefano had also served as Senior Venture Officer for the Edison Innovation Fund, implemented through the New Jersey Economic Development Authority that provided funding for early-stage life sciences companies. Industry experience includes laboratory research for Johns Hopkins Hospital and the Department of Defense.
Ms. di Stefano received a Masters of Science degree, in Business, from Johns Hopkins University in 1986, and a Bachelor of Arts from the University of Delaware in 1984 with a minor in biology.
I used to run a limited partnership, boutique hedge fund in the 90s. Retired in 2000 and moved from New York City to Toronto, Canada, got married, raised a family and basically settled down. After a few years in Toronto, my wife got tired of the city’s 8 months of cold weather and insisted that we move to a city where there are 8 months of warm and balmy weather. So we settled on San Diego, CA and moved here in 2005 and now call this lovely city with the most perfect weather, home…
It’s been 4 years since I started this blog back in December of 2012…though I did not actively post this year, my plan for 2017 is to adopt a slightly more hands-on role…we shall see…
For those new here, a quick background…I started Options2Wealth as a 6 month experiment in equity options trading with a seed capital of $10,000…my trades were transparent enough that I would first announce my trade(s) here before placing them…once my intention was time-stamped on this blog, I would then place the actual trade and post a screenshot of its execution as proof…
How well did I do? Well, if you really want to know, you will need to go through the first 56 posts, all saved here for posterity by the wonderful internet…every single trade, buy or sell, and the reason(s) behind the trade along with supporting charts, etc…it was one heck of a ride… :) A few of the blog’s readers piggy-backed on my trades and did pretty good for themselves, later sharing their individual testimonials, in the comments section, with everyone here … ;)
Last year, on a lark, my wife and I started a new company in the high-end consumer space…our company, iBBQ, sells a line of very unique, hand-crafted barbecue tables called the Angara…our tables are built by us at a facility in Michigan…recently, the Robb Report, the Bible of luxury living, dubbed it the "Ultimate in Outdoor Entertaining.” … check us out at http://www.ibbq.com ...and should you be interested in bringing the world's most stunning and versatile outdoor dining table to your backyard, contact me here and I may be able to make you an offer too difficult to turn down... :)
Best of Luck to All!
December 27, 2016
Michael Murphy grew up in Newark, Delaware, which a sign at the city limits proclaimed: “The Educatoinal Center of the State.” After graduating from the public schools he earned an A.B. cum laude from Harvard College and began working as a COBOL mainframe programmer on an IBM 1401 in the mid-1960s. Lured to California by the Summer of Love and better music than American Bandstand in nearby Philadelphia, he became a systems analyst and programmer for American Express, assigned to help integrate their newly-acquired San Francisco investment operations with the parent company's systems in New York. As that project ended early in 1970, a fortuitous opportunity to make a career change to Security Analyst opened up, and he leaped at the chance. His first recommendation was to sell Memorex at $172 at the very bottom of the 1969-1970 bear market. During the subsequent two-year market rally, Memorex went to $2 a share, thus convincing him that it is indeed a market of stocks rather than a stock market.
He earned his Chartered Financial Analyst (CFA) designation in 1975, the same year The Capital Group/American Funds acquired the American Express mutual fund group. He commuted to Capital in Los Angeles for over five years, getting on a first-name basis with many flight attendants. After the introduction of the IBM PC in April 1981, he left Capital to found the California Technology Stock Letter. In 1997 he also became the founding editor of Technology Investing, which acquired CTSL in 2003 and changed its name to New World Investor in 2007.
In the 1970s he invented and patented a stock value calculator, and in the 1980s he served as the CEO of two software companies. In 1997 he authored the business best-seller Every Investor's Guide to High-Tech Stocks and Mutual Funds, and he has a forthcoming book on investing in a hyperinflation. In addition to investing, his interests include a biodynamic, organic permaculture farm to raise rare-breed animals, heritage seed crops and children. For many years he held the Class I/E record for electric cars at the Bonneville Salt Flats, and in 2001 he narrowly missed the world record for electric hydroplanes. He expects to go back to Bonneville in 2019 to reclaim the electric car record with his then-16 year old daughter driving. You are all invited to watch or help out.
Earned a Doctorate in Pharmacy (Pharm.D.) in 2010 and Pre-Pharmacy/B.S. in Molecular Biology in 2006. Over six years of direct experience in translational research in oncology investigating the molecular/cellular mechanisms of carcinogenesis focused on biomarker identification and validation working in a multi-disciplinary matrix environment across academia, contract research organizations and industry.
Analyst Tip Ranks: https://www.tipranks.com/experts/dr.-paul-nunzio-desantis%252C-pharm.d
I am currently an individual investor with focus on event-driven trading and long-short opportunities. I graduated Emory University in 2009 and am also a finance Phd dropout from UCLA Anderson. I could be reached at email@example.com
Value Digger holds MSc. in Electrical Engineering, speaks four languages and has lived in the U.S. for many years. Also, he is a full-time investor and a freelance writer with one of the highest Followers per Article (F/A) rates in Seeking Alpha. His F/A rate in Seeking Alpha is above 30.
After creating "Nathan's Bulletin" (a subscription-based investment guide for investors who can't afford a financial advisor), Value Digger launched a subscription-based Premium Service in Seeking Alpha entitled "A Fundamental Investor's Stock Club" which includes an unparalleled, actively-managed and high-return Portfolio of unknown and/or underfollowed stocks. Regularly updated and detailed lists in his Premium Posts PROVE these high returns. For reference, when Value Digger was managing money in the early 2000s, his Portfolio's annual ROI consistently exceeded 50%. His Premium Research is based on a comprehensive review of company-specific factors, macro conditions, competitors and the industry trends.
When it comes to his publicly-available picks and his free Seeking Alpha articles, Value Digger is ranked in the TOP-50 with a success rate of over 70%, an average return per recommendation of over 20% and a 5-star rating according to TipRanks.com, which is the highest category quality ranking used to evaluate financial experts. TipRanks.com is a comprehensive investing tool that allows private investors and day traders to see the measured performance of anyone who publicly provides financial advice. TipRanks.com collects data, evaluates and ranks 9,000 financial experts worldwide.
After almost 30 years of investing experience in the international markets (U.S., Canada, Australia, Europe), Value Digger has formulated a deep understanding of valuation analysis and his investment philosophy is firmly grounded in Ben Graham-style value-oriented opportunities that often have an assymetric risk/reward profile. On that front, he has created a unique proprietary database with thousands of publicly-traded companies per sector, which helps him spot the bargains and the bubbles before many investors find them.